Insider Selling: Stryker Corp. (SYK) Director Sells 12,000 Shares of Stock
Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 12,000 shares of the firm’s stock in a transaction on Monday, October 17th. The stock was sold at an average price of $113.95, for a total transaction of $1,367,400.00. Following the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at $22,008,530.90. The sale was disclosed in a document filed with the SEC, which is available through this link.
Shares of Stryker Corp. (NYSE:SYK) traded down 0.07% during midday trading on Monday, hitting $113.57. 721,669 shares of the company traded hands. The stock’s 50-day moving average is $115.22 and its 200 day moving average is $114.11. Stryker Corp. has a 12-month low of $86.68 and a 12-month high of $123.55. The stock has a market capitalization of $42.51 billion, a P/E ratio of 26.77 and a beta of 0.72.
Stryker Corp. (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.37 by $0.02. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. The company earned $2.84 billion during the quarter, compared to analysts’ expectations of $2.79 billion. On average, analysts expect that Stryker Corp. will post $5.76 earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/insider-selling-stryker-corp-syk-director-sells-12000-shares-of-stock.html
The firm also recently declared a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be given a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 1.34%. The ex-dividend date of this dividend is Wednesday, September 28th. Stryker Corp.’s dividend payout ratio is 35.85%.
Several large investors have recently modified their holdings of the company. GaveKal Capital LLC boosted its stake in shares of Stryker Corp. by 18.7% in the third quarter. GaveKal Capital LLC now owns 78,290 shares of the medical technology company’s stock valued at $9,114,000 after buying an additional 12,347 shares in the last quarter. CWM LLC boosted its stake in shares of Stryker Corp. by 56.0% in the third quarter. CWM LLC now owns 1,949 shares of the medical technology company’s stock valued at $227,000 after buying an additional 700 shares in the last quarter. Koshinski Asset Management Inc. boosted its stake in shares of Stryker Corp. by 4.3% in the third quarter. Koshinski Asset Management Inc. now owns 8,866 shares of the medical technology company’s stock valued at $1,032,000 after buying an additional 367 shares in the last quarter. St. Johns Investment Management Company LLC boosted its stake in shares of Stryker Corp. by 3.6% in the third quarter. St. Johns Investment Management Company LLC now owns 10,448 shares of the medical technology company’s stock valued at $1,216,000 after buying an additional 361 shares in the last quarter. Finally, Harwood Advisory Group LLC boosted its stake in shares of Stryker Corp. by 18.0% in the third quarter. Harwood Advisory Group LLC now owns 10,934 shares of the medical technology company’s stock valued at $1,273,000 after buying an additional 1,669 shares in the last quarter. Institutional investors own 75.50% of the company’s stock.
Several research analysts have weighed in on SYK shares. Zacks Investment Research lowered shares of Stryker Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, September 27th. Canaccord Genuity reaffirmed a “buy” rating and issued a $130.00 price target on shares of Stryker Corp. in a report on Sunday, July 24th. Credit Suisse Group AG reaffirmed an “outperform” rating and issued a $124.00 price target (up from $110.00) on shares of Stryker Corp. in a report on Tuesday, July 19th. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $119.00 price target on shares of Stryker Corp. in a report on Friday, July 22nd. Finally, Brean Capital reaffirmed a “buy” rating and issued a $125.00 price target (up from $121.00) on shares of Stryker Corp. in a report on Monday, July 25th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $117.91.
Stryker Corp. Company Profile
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related companies with MarketBeat.com's FREE daily email newsletter.